NOV 08, 2020 7:30 AM PST

Psychedelic Mushrooms Effectively Treat Major Depression

WRITTEN BY: Annie Lennon

image

Over 17 million people in the US and 300 million people worldwide are estimated to have experienced major depression. Now, researchers from Johns Hopkins University have found that two doses of psilocybin, the psychoactive ingredient in ‘magic mushrooms’, coupled with psychotherapy, can significantly reduce depressive symptoms. 

“The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” says Alan Davis, assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. 

“Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard’ placebo-controlled clinical trials.”

For the study, the researchers involved 24 people with a long-term history of depression, most of whom experienced persistent depressive symptoms for around two years prior to enrolling in the study. The average age of the participants was 39, while 16 were women, and 22 considered themselves as ‘white’. 

The treatment consisted of two psilocybin sessions lasting five hours each monitored by two clinicians taken two weeks apart between August 2017 and April 2019. Prior to the treatment and at one week and 4-week follow-ups from treatment completion, participants were assessed with a standard depression assessment tool known as the GRID-Hamilton Depression Rating Scale. 

All in all, 67% of participants showed more than a 50% reduction in depressive symptoms at a one-week follow-up. At the four-week follow-up, this number increased to 71% of participants. On top of this, at the four-week follow-up, 54% of participants no longer qualified for being depressed.

The researchers now say that they will follow the participants for another year to see how long the antidepressant effects of psilocybin-assisted psychotherapy last, and will report their results in a later publication. 

 

Sources: Neuroscience NewsNPR

 

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
SEP 27, 2021
Health & Medicine
Gender-affirmation Surgery in Transgender Patients - Evidence for Regret?
SEP 27, 2021
Gender-affirmation Surgery in Transgender Patients - Evidence for Regret?
Gender-affirming care is a broad term used to describe medical, psychosocial, and surgical interventions delivered to tr ...
SEP 28, 2021
Drug Discovery & Development
The FDA approves drug to treat a bad cholesterol in children
SEP 28, 2021
The FDA approves drug to treat a bad cholesterol in children
Familial hypercholesterolemia (FH) is a genetic disorder that afflicts approximately 1 in 250 people. Interestingly, whi ...
NOV 01, 2021
Genetics & Genomics
Genetic Connnections to Osteoerthritis
NOV 01, 2021
Genetic Connnections to Osteoerthritis
Osteoarthritis is a painful condition in which joints become inflamed, leading them to feel stiff or sore, especially in ...
NOV 04, 2021
Cancer
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
NOV 04, 2021
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
Despite the incremental success immune checkpoint inhibitors (ICI) have attributed to the cancer treatment landscape rec ...
NOV 10, 2021
Drug Discovery & Development
Inflammation during pregnancy can affect normal brain development
NOV 10, 2021
Inflammation during pregnancy can affect normal brain development
During pregnancy the growing embryo and fetus undergo remarkable and quick developmental. Around 5 weeks after ...
NOV 16, 2021
Health & Medicine
Psilocybin and Cannabis to Treat Anxiety and Addiction
NOV 16, 2021
Psilocybin and Cannabis to Treat Anxiety and Addiction
Johns Hopkins University Center for Psychedelic and Consciousness Research just received a $4.9 million grant to study h ...
Loading Comments...